The Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161–76.
Article
Google Scholar
Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, Yanny I, Razavi H, Vickerman P. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16(7):797–808.
Article
PubMed
Google Scholar
Vallet-Pichard A, Pol S. Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection. J Hepatol. 2006;44(1 Suppl):S28-34.
Article
PubMed
Google Scholar
Lo-Re V, Kallan MJ, Tate JP, Localio AR, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med. 2014;160(6):369–79.
PubMed
Google Scholar
López-Diéguez M, Montes ML, Pascual-Pareja JF, Quereda C, Von Wichmann MA, Berenguer J, Tural C, Hernando A, González-García J, Serrano L, et al. The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients. AIDS. 2011;25(7):899–904.
Article
PubMed
Google Scholar
Macias J, Berenguer J, Japon MA, Giron JA, Rivero A, Lopez-Cortes LF, Moreno A, Gonzalez-Serrano M, Iribarren JA, Ortega E, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology. 2009;50(4):1056–63.
Article
CAS
PubMed
Google Scholar
Ingiliz P, Rockstroh JK. Natural history of liver disease and effect of hepatitis C virus on HIV disease progression. Curr Opin HIV AIDS. 2015;10(5):303–8.
Article
CAS
PubMed
Google Scholar
Naggie S. Hepatitis C virus, inflammation, and cellular aging: turning back time. Top Antivir Med. 2017;25(1):3–6.
PubMed
PubMed Central
Google Scholar
Shin EC, Sung PS, Park SH. Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol. 2016;16(8):509–23.
Article
CAS
PubMed
Google Scholar
Pandiyan P, Younes SA, Ribeiro SP, Talla A, McDonald D, Bhaskaran N, Levine AD, Weinberg A, Sekaly RP. Mucosal Regulatory T Cells and T Helper 17 Cells in HIV-Associated Immune Activation. Front Immunol. 2016;7:228.
PubMed
PubMed Central
Google Scholar
Miles B, Miller SM, Connick E. CD4 t follicular helper and regulatory cell dynamics and function in HIV infection. Front Immunol. 2016;7:659.
Article
PubMed
PubMed Central
CAS
Google Scholar
De Biasi S, Bianchini E, Nasi M, Digaetano M, Gibellini L, Carnevale G, Borghi V, Guaraldi G, Pinti M, Mussini C, et al. Th1 and Th17 proinflammatory profile characterizes invariant natural killer T cells in virologically suppressed HIV+ patients with low CD4+/CD8+ ratio. AIDS. 2016;30(17):2599–610.
Article
PubMed
CAS
Google Scholar
Fernandes JR, Berthoud TK, Kumar A, Angel JB. IL-23 signaling in Th17 cells is inhibited by HIV infection and is not restored by HAART: Implications for persistent immune activation. PLoS ONE. 2017;12(11):e0186823.
Article
PubMed
PubMed Central
CAS
Google Scholar
DaFonseca S, Niessl J, Pouvreau S, Wacleche VS, Gosselin A, Cleret-Buhot A, Bernard N, Tremblay C, Jenabian MA, Routy JP, et al. Impaired Th17 polarization of phenotypically naive CD4(+) T-cells during chronic HIV-1 infection and potential restoration with early ART. Retrovirology. 2015;12:38.
Article
PubMed
PubMed Central
CAS
Google Scholar
Mahnke YD, Fletez-Brant K, Sereti I, Roederer M. Reconstitution of Peripheral T Cells by Tissue-Derived CCR4+ central memory cells following HIV-1 antiretroviral therapy. Pathog Immun. 2016;1(2):260–90.
Article
PubMed
PubMed Central
Google Scholar
de Paula HHS, Ferreira ACG, Caetano DG, Delatorre E, Teixeira SLM, Coelho LE, Joao EG, de Andrade MM, Cardoso SW, Grinsztejn B, et al. Reduction of inflammation and T cell activation after 6 months of cART initiation during acute, but not in early chronic HIV-1 infection. Retrovirology. 2018;15(1):76.
Article
PubMed
PubMed Central
CAS
Google Scholar
Merlini E, Tincati C, Biasin M, Saulle I, Cazzaniga FA, d’Arminio Monforte A, Cappione AJ 3rd, Snyder-Cappione J, Clerici M, Marchetti GC. Stimulation of PBMC and monocyte-derived macrophages via toll-like receptor activates innate immune pathways in HIV-infected patients on virally suppressive combination antiretroviral therapy. Front Immunol. 2016;7:614.
Article
PubMed
PubMed Central
CAS
Google Scholar
Mudd JC, Brenchley JM. Gut mucosal barrier dysfunction, microbial dysbiosis, and their role in HIV-1 disease progression. J Infect Dis. 2016;214(Suppl 2):S58-66.
Article
CAS
PubMed
PubMed Central
Google Scholar
Tincati C, Merlini E, Braidotti P, Ancona G, Savi F, Tosi D, Borghi E, Callegari ML, Mangiavillano B, Barassi A, et al. Impaired gut junctional complexes feature late-treated individuals with suboptimal CD4+ T-cell recovery upon virologically suppressive combination antiretroviral therapy. AIDS. 2016;30(7):991–1003.
Article
CAS
PubMed
Google Scholar
Hunt PW, Lee SA, Siedner MJ. Immunologic Biomarkers, Morbidity, and Mortality in Treated HIV Infection. J Infect Dis. 2016;214(Suppl 2):S44-50.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hart BB, Nordell AD, Okulicz JF, Palfreeman A, Horban A, Kedem E, Neuhaus J, Jacobs DR Jr, Duprez DA, Neaton JD, et al. Inflammation-related morbidity and mortality among hiv-positive adults: how extensive is it? J Acquir Immune Defic Syndr. 2018;77(1):1–7.
Article
PubMed
PubMed Central
Google Scholar
Liang TJ, Ghany MG. Therapy of hepatitis C–back to the future. N Engl J Med. 2014;370(21):2043–7.
Article
PubMed
PubMed Central
CAS
Google Scholar
Panel A-IHG: Hepatitis C Guidance 2018 Update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C Virus Infection. Clin Infect Dis 2018, 67(10):1477–1492.
European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L: EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69(2):461–511.
Article
Google Scholar
Berenguer J, Gil-Martin A, Jarrin I, Moreno A, Dominguez L, Montes M, Aldamiz-Echevarria T, Tellez MJ, Santos I, Benitez L, et al. All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV-coinfected subjects in real-world practice: Madrid coinfection registry findings. Hepatology. 2018;68(1):32–47.
Article
CAS
PubMed
Google Scholar
Berenguer J, Rodriguez E, Miralles P, Von Wichmann MA, Lopez-Aldeguer J, Mallolas J, Galindo MJ, Van Den Eynde E, Tellez MJ, Quereda C, et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus. Clin Infect Dis. 2012;55(5):728–36.
Article
CAS
PubMed
Google Scholar
Berenguer J, Rodriguez-Castellano E, Carrero A, Von Wichmann MA, Montero M, Galindo MJ, Mallolas J, Crespo M, Tellez MJ, Quereda C, et al. Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology. 2017;66(2):344–56.
Article
CAS
PubMed
Google Scholar
Liu Z, Wei X, Chen T, Huang C, Liu H, Wang Y. Characterization of fibrosis changes in chronic hepatitis C patients after virological cure: a systematic review with meta-analysis. J Gastroenterol Hepatol. 2017;32(3):548–57.
Article
PubMed
Google Scholar
Labarga P, Fernandez-Montero JV, de Mendoza C, Barreiro P, Pinilla J, Soriano V. Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV-coinfected patients. Antivir Ther. 2015;20(3):329–34.
Article
PubMed
Google Scholar
Mira JA, Neukam K, Lopez-Cortes LF, Rivero-Juarez A, Tellez F, Giron-Gonzalez JA, de los Santos-Gil I, Ojeda-Burgos G, Merino D, Rios-Villegas MJ et al: Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia. Eur J Clin Microbiol Infect Dis 2015; 34(9):1879–1884.
Salmon-Ceron D, Nahon P, Layese R, Bourcier V, Sogni P, Bani-Sadr F, Audureau E, Merchadou L, Dabis F, Wittkop L et al: Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients. Hepatology 2018.
Allaire M, Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Ledinghen V, et al. Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication. Hepatology. 2018;68(4):1245–59.
Article
PubMed
Google Scholar
European Association for Study of L. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60(2):392–420.
Article
Google Scholar
Rosenberg BR, Freije CA, Imanaka N, Chen ST, Eitson JL, Caron R, Uhl SA, Zeremski M, Talal A, Jacobson IM, et al. Genetic Variation at IFNL4 influences extrahepatic interferon-stimulated gene expression in chronic HCV Patients. J Infect Dis. 2018;217(4):650–5.
Article
CAS
PubMed
Google Scholar
Rosenberg BR, Depla M, Freije CA, Gaucher D, Mazouz S, Boisvert M, Bedard N, Bruneau J, Rice CM, Shoukry NH. Longitudinal transcriptomic characterization of the immune response to acute hepatitis C virus infection in patients with spontaneous viral clearance. PLoS Pathog. 2018;14(9):e1007290.
Article
PubMed
PubMed Central
CAS
Google Scholar
Lu MY, Huang CI, Hsieh MY, Hsieh TJ, Hsi E, Tsai PC, Tsai YS, Lin CC, Hsieh MH, Liang PC, et al. Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapy. Oncotarget. 2016;7(38):61325–35.
Article
PubMed
PubMed Central
Google Scholar
Carlton-Smith C, Holmes JA, Naggie S, Lidofsky A, Lauer GM, Kim AY, Chung RT. of the AAsg: IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR. J Viral Hepat. 2018;25(5):465–72.
Article
CAS
PubMed
Google Scholar
Alao H, Cam M, Keembiyehetty C, Zhang F, Serti E, Suarez D, Park H, Fourie NH, Wright EC, Henderson WA, et al. Baseline intrahepatic and peripheral innate immunity are associated with hepatitis C virus clearance during direct-acting antiviral therapy. Hepatology. 2018;68(6):2078–88.
Article
CAS
PubMed
Google Scholar
Waldron PR, Holodniy M. Peripheral blood mononuclear cell gene expression remains broadly altered years after successful interferon-based hepatitis C virus treatment. J Immunol Res. 2015;2015:958231.
Article
PubMed
PubMed Central
CAS
Google Scholar
Garcia-Broncano P, Medrano LM, Berenguer J, Brochado-Kith O, Gonzalez-Garcia J, Jimenez-Sousa MA, Quereda C, Sanz J, Tellez MJ, Diaz L, et al. Mild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: a prospective study. J Infect. 2020;80(1):99–110.
Article
CAS
PubMed
Google Scholar
Hart SN, Therneau TM, Zhang Y, Poland GA, Kocher JP. Calculating sample size estimates for RNA sequencing data. J Comput Biol. 2013;20(12):970–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kottilil S, Yan MY, Reitano KN, Zhang X, Lempicki R, Roby G, Daucher M, Yang J, Cortez KJ, Ghany M, et al. Human immunodeficiency virus and hepatitis C infections induce distinct immunologic imprints in peripheral mononuclear cells. Hepatology. 2009;50(1):34–45.
Article
CAS
PubMed
Google Scholar
Roque-Cuellar MC, Sanchez B, Garcia-Lozano JR, Praena-Fernandez JM, Marquez-Galan JL, Nunez-Roldan A, Aguilar-Reina J. Hepatitis C virus-specific cellular immune responses in sustained virological responders with viral persistence in peripheral blood mononuclear cells. Liver Int. 2014;34(6):e80-88.
Article
CAS
PubMed
Google Scholar
Chung H, Watanabe T, Kudo M, Chiba T. Correlation between hyporesponsiveness to Toll-like receptor ligands and liver dysfunction in patients with chronic hepatitis C virus infection. J Viral Hepat. 2011;18(10):e561-567.
Article
CAS
PubMed
Google Scholar
Cabral ES, Gelderblom H, Hornung RL, Munson PJ, Martin R, Marques AR. Borrelia burgdorferi lipoprotein-mediated TLR2 stimulation causes the down-regulation of TLR5 in human monocytes. J Infect Dis. 2006;193(6):849–59.
Article
CAS
PubMed
Google Scholar
Meng P, Zhao S, Niu X, Fu N, Su S, Wang R, Zhang Y, Qiao L, Nan Y. Involvement of the Interleukin-23/Interleukin-17 axis in chronic hepatitis C virus infection and its treatment responses. Int J Mol Sci. 2016;17:7.
Google Scholar
Ravindran MS, Bagchi P, Cunningham CN, Tsai B. Opportunistic intruders: how viruses orchestrate ER functions to infect cells. Nat Rev Microbiol. 2016;14(7):407–20.
Article
CAS
PubMed
PubMed Central
Google Scholar
Choukhi A, Ung S, Wychowski C, Dubuisson J. Involvement of endoplasmic reticulum chaperones in the folding of hepatitis C virus glycoproteins. J Virol. 1998;72(5):3851–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lai CK, Jeng KS, Machida K, Lai MM. Hepatitis C virus egress and release depend on endosomal trafficking of core protein. J Virol. 2010;84(21):11590–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ikeda A, Shimizu T, Matsumoto Y, Fujii Y, Eso Y, Inuzuka T, Mizuguchi A, Shimizu K, Hatano E, Uemoto S, et al. Leptin receptor somatic mutations are frequent in HCV-infected cirrhotic liver and associated with hepatocellular carcinoma. Gastroenterology. 2014;146(1):222–32.
Article
CAS
PubMed
Google Scholar
Wang J, Kang R, Huang H, Xi X, Wang B, Wang J, Zhao Z. Hepatitis C virus core protein activates autophagy through EIF2AK3 and ATF6 UPR pathway-mediated MAP1LC3B and ATG12 expression. Autophagy. 2014;10(5):766–84.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ren H, Elgner F, Himmelsbach K, Akhras S, Jiang B, Medvedev R, Ploen D, Hildt E. Identification of syntaxin 4 as an essential factor for the hepatitis C virus life cycle. Eur J Cell Biol. 2017;96(6):542–52.
Article
CAS
PubMed
Google Scholar
Phatarpekar PV, Billadeau DD. Molecular regulation of the plasma membrane-proximal cellular steps involved in NK cell cytolytic function. J Cell Sci. 2020;133:5.
Article
Google Scholar
Lopez-Cortes LF, Trujillo-Rodriguez M, Baez-Palomo A, Benmarzouk-Hidalgo OJ, Dominguez-Molina B, Milanes-Guisado Y, Espinosa N, Viciana P, Gutierrez-Valencia A. Eradication of Hepatitis C Virus (HCV) Reduces Immune Activation, Microbial Translocation, and the HIV DNA Level in HIV/HCV-Coinfected Patients. J Infect Dis. 2018;218(4):624–32.
Article
CAS
PubMed
Google Scholar
Shindiapina P, Ahmed EH, Mozhenkova A, Abebe T, Baiocchi RA. Immunology of EBV-Related Lymphoproliferative Disease in HIV-Positive Individuals. Front Oncol. 2020;10:1723.
Article
PubMed
PubMed Central
Google Scholar
Eguchi A. De Mollerat Du Jeu X, Johnson CD, Nektaria A, Feldstein AE: Liver Bid suppression for treatment of fibrosis associated with non-alcoholic steatohepatitis. J Hepatol. 2016;64(3):699–707.
Article
CAS
PubMed
Google Scholar
Bao L, Zhang M, Han S, Zhan Y, Guo W, Teng F, Liu F, Guo M, Zhang L, Ding G, et al. MicroRNA-500a promotes the progression of hepatocellular carcinoma by post-transcriptionally targeting BID. Cell Physiol Biochem. 2018;47(5):2046–55.
Article
CAS
PubMed
Google Scholar
Wree A, Johnson CD, Font-Burgada J, Eguchi A, Povero D, Karin M, Feldstein AE. Hepatocyte-specific Bid depletion reduces tumor development by suppressing inflammation-related compensatory proliferation. Cell Death Differ. 2015;22(12):1985–94.
Article
CAS
PubMed
PubMed Central
Google Scholar
Crux NB, Elahi S. Human Leukocyte Antigen (HLA) and immune regulation: how do classical and non-classical hla alleles modulate immune response to human immunodeficiency virus and hepatitis C virus infections? Front Immunol. 2017;8:832.
Article
PubMed
PubMed Central
CAS
Google Scholar
Ramsuran V, Naranbhai V, Horowitz A, Qi Y, Martin MP, Yuki Y, Gao X, Walker-Sperling V, Del Prete GQ, Schneider DK, et al. Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells. Science. 2018;359(6371):86–90.
Article
CAS
PubMed
PubMed Central
Google Scholar
Huda N, Liu G, Hong H, Yan S, Khambu B, Yin XM. Hepatic senescence, the good and the bad. World J Gastroenterol. 2019;25(34):5069–81.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ohkoshi S, Yano M, Matsuda Y. Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy. World J Gastroenterol. 2015;21(42):12150–6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Diez-Fuertes F, De La Torre-Tarazona HE, Calonge E, Pernas M, Alonso-Socas MDM, Capa L, Garcia-Perez J, Sakuntabhai A, Alcami J. Transcriptome sequencing of peripheral blood mononuclear cells from elite controller-long term non progressors. Sci Rep. 2019;9(1):14265.
Article
PubMed
PubMed Central
CAS
Google Scholar
Leng J, Ho HP, Buzon MJ, Pereyra F, Walker BD, Yu XG, Chang EJ, Lichterfeld M. A cell-intrinsic inhibitor of HIV-1 reverse transcription in CD4(+) T cells from elite controllers. Cell Host Microbe. 2014;15(6):717–28.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jiang G, Dandekar S. Targeting NF-kappaB signaling with protein kinase C agonists as an emerging strategy for combating HIV latency. AIDS Res Hum Retroviruses. 2015;31(1):4–12.
Article
CAS
PubMed
PubMed Central
Google Scholar
O’Neil BH, Buzkova P, Farrah H, Kashatus D, Sanoff H, Goldberg RM, Baldwin AS, Funkhouser WK. Expression of nuclear factor-kappaB family proteins in hepatocellular carcinomas. Oncology. 2007;72(1–2):97–104.
Article
CAS
PubMed
Google Scholar
Sookoian S, Pirola CJ. Systems biology elucidates common pathogenic mechanisms between nonalcoholic and alcoholic-fatty liver disease. PLoS ONE. 2013;8(3):e58895.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wang M, Yang W, Chen Y, Wang J, Tan J, Qiao W. Cellular RelB interacts with the transactivator Tat and enhance HIV-1 expression. Retrovirology. 2018;15(1):65.
Article
PubMed
PubMed Central
CAS
Google Scholar
Zhou D, Huang W, Wei J, Zhang J, Liu Z, Ji R, Ge S, Xiao M, Fan Y, Lu C. RelB promotes liver fibrosis via inducing the release of injury-associated inflammatory cytokines. J Cell Mol Med. 2020;24(11):6008–14.
Article
CAS
PubMed
PubMed Central
Google Scholar
Elssner C, Goeppert B, Longerich T, Scherr AL, Stindt J, Nanduri LK, Rupp C, Kather JN, Schmitt N, Kautz N, et al. Nuclear translocation of RELB is increased in diseased human liver and promotes ductular reaction and biliary fibrosis in mice. Gastroenterology. 2019;156(4):1190–205.
Article
PubMed
Google Scholar
Hettinghouse A, Liu R, Liu CJ. Multifunctional molecule ERp57: From cancer to neurodegenerative diseases. Pharmacol Ther. 2018;181:34–48.
Article
CAS
PubMed
Google Scholar
Zhao Q, Feng Y, Jia X, Yin L, Zheng Y, Ouyang D, Zhou H, Zhang L. Proteome analysis of hepatic non-parenchymal cells of immune liver fibrosis rats. Sci China Life Sci. 2014;57(3):303–14.
Article
CAS
PubMed
Google Scholar
Kondo R, Ishino K, Wada R, Takata H, Peng WX, Kudo M, Kure S, Kaneya Y, Taniai N, Yoshida H, et al. Downregulation of protein disulfideisomerase A3 expression inhibits cell proliferation and induces apoptosis through STAT3 signaling in hepatocellular carcinoma. Int J Oncol. 2019;54(4):1409–21.
CAS
PubMed
Google Scholar
Ko E, Kim JS, Ju S, Seo HW, Chang Y, Kang JA, Park SG, Jung G. Oxidatively modified protein-disulfide isomerase-associated 3 promotes dyskerin pseudouridine synthase 1-mediated malignancy and survival of hepatocellular carcinoma cells. Hepatology. 2018;68(5):1851–64.
Article
CAS
PubMed
Google Scholar
Cheng D, Zhao L, Zhang L, Jiang Y, Tian Y, Xiao X, Gong G. p53 controls hepatitis C virus non-structural protein 5A-mediated downregulation of GADD45α expression via the NF-κB and PI3K-Akt pathways. J Gen Virol. 2013;94(Pt 2):326–35.
Article
CAS
PubMed
PubMed Central
Google Scholar
Mitchell JK, Midkiff BR, Israelow B, Evans MJ, Lanford RE, Walker CM, Lemon SM, McGivern DR. Hepatitis C Virus Indirectly Disrupts DNA Damage-Induced p53 Responses by Activating Protein Kinase R. mBio. 2017;8:2.
Google Scholar
Jin Y, Lee WY, Toh ST, Tennakoon C, Toh HC, Chow PK, Chung AY, Chong SS, Ooi LL, Sung WK, et al. Comprehensive analysis of transcriptome profiles in hepatocellular carcinoma. J Transl Med. 2019;17(1):273.
Article
PubMed
PubMed Central
CAS
Google Scholar
Tannapfel A, Wasner M, Krause K, Geissler F, Katalinic A, Hauss J, Mossner J, Engeland K, Wittekind C. Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma. J Natl Cancer Inst. 1999;91(13):1154–8.
Article
CAS
PubMed
Google Scholar
Bechmann LP, Gieseler RK, Sowa JP, Kahraman A, Erhard J, Wedemeyer I, Emons B, Jochum C, Feldkamp T, Gerken G, et al. Apoptosis is associated with CD36/fatty acid translocase upregulation in non-alcoholic steatohepatitis. Liver Int. 2010;30(6):850–9.
Article
CAS
PubMed
Google Scholar
Chang SC, Choo WQ, Toh HC, Ding JL. SAG-UPS attenuates proapoptotic SARM and Noxa to confer survival advantage to early hepatocellular carcinoma. Cell Death Discov. 2015;1:15032.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhu H, Yang W, He LJ, Ding WJ, Zheng L, Liao SD, Huang P, Lu W, He QJ, Yang B. Upregulating Noxa by ER stress, celastrol exerts synergistic anti-cancer activity in combination with ABT-737 in human hepatocellular carcinoma cells. PLoS ONE. 2012;7(12):e52333.
Article
CAS
PubMed
PubMed Central
Google Scholar
Schulien I, Hockenjos B, Schmitt-Graeff A, Perdekamp MG, Follo M, Thimme R, Hasselblatt P. The transcription factor c-Jun/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating Osteopontin expression. Cell Death Differ. 2019;26(9):1688–99.
Article
CAS
PubMed
PubMed Central
Google Scholar
DeAngelis RA, Markiewski MM, Taub R, Lambris JD. A high-fat diet impairs liver regeneration in C57BL/6 mice through overexpression of the NF-kappaB inhibitor IkappaBalpha. Hepatology. 2005;42(5):1148–57.
Article
CAS
PubMed
Google Scholar
Luedde T, Schwabe RF. NF-kappaB in the liver–linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2011;8(2):108–18.
Article
CAS
PubMed
PubMed Central
Google Scholar
Taura M, Kudo E, Kariya R, Goto H, Matsuda K, Hattori S, Vaeteewoottacharn K, McDonald F, Suico MA, Shuto T, et al. COMMD1/Murr1 reinforces HIV-1 latent infection through IkappaB-alpha stabilization. J Virol. 2015;89(5):2643–58.
Article
PubMed
CAS
Google Scholar
Kogan M, Deshmane S, Sawaya BE, Gracely EJ, Khalili K, Rappaport J. Inhibition of NF-kappaB activity by HIV-1 Vpr is dependent on Vpr binding protein. J Cell Physiol. 2013;228(4):781–90.
Article
CAS
PubMed
PubMed Central
Google Scholar
Vallejo-Diaz J, Chagoyen M, Olazabal-Moran M, Gonzalez-Garcia A, Carrera AC. The opposing roles of PIK3R1/p85alpha and PIK3R2/p85beta in cancer. Trends Cancer. 2019;5(4):233–44.
Article
CAS
PubMed
Google Scholar
Muhanna N, Doron S, Wald O, Horani A, Eid A, Pappo O, Friedman SL, Safadi R. Activation of hepatic stellate cells after phagocytosis of lymphocytes: a novel pathway of fibrogenesis. Hepatology. 2008;48(3):963–77.
Article
CAS
PubMed
Google Scholar
Wang R, Wang X, Zhuang L. Gene expression profiling reveals key genes and pathways related to the development of non-alcoholic fatty liver disease. Ann Hepatol. 2016;15(2):190–9.
Article
CAS
PubMed
Google Scholar
Grise F, Bidaud A, Moreau V. Rho GTPases in hepatocellular carcinoma. Biochim Biophys Acta. 2009;1795(2):137–51.
CAS
PubMed
Google Scholar
Wang H, Lafdil F, Kong X, Gao B. Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target. Int J Biol Sci. 2011;7(5):536–50.
Article
CAS
PubMed
PubMed Central
Google Scholar
Handa P, Vemulakonda AL, Maliken BD, Morgan-Stevenson V, Nelson JE, Dhillon BK, Hennessey KA, Gupta R, Yeh MM, Kowdley KV. Differences in hepatic expression of iron, inflammation and stress-related genes in patients with nonalcoholic steatohepatitis. Ann Hepatol. 2017;16(1):77–85.
Article
CAS
PubMed
Google Scholar
Lee C, Cheung ST. STAT3: An Emerging Therapeutic Target for Hepatocellular Carcinoma. Cancers (Basel). 2019;11:11.
Google Scholar
Lee MS, Hanspers K, Barker CS, Korn AP, McCune JM. Gene expression profiles during human CD4+ T cell differentiation. Int Immunol. 2004;16(8):1109–24.
Article
CAS
PubMed
Google Scholar
Helgeland H, Gabrielsen I, Akselsen H, Sundaram AYM, Flam ST, Lie BA. Transcriptome profiling of human thymic CD4+ and CD8+ T cells compared to primary peripheral T cells. BMC Genomics. 2020;21(1):350.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nirei K, Kanda T, Nakamura H, Matsuoka S, Takayama T, Sugitani M, Moriyama M. Persistent hepatic inflammation plays a role in hepatocellular carcinoma after sustained virological response in patients with HCV Infection. Int J Med Sci. 2018;15(5):466–74.
Article
CAS
PubMed
PubMed Central
Google Scholar
Perez S, Kaspi A, Domovitz T, Davidovich A, Lavi-Itzkovitz A, Meirson T, Alison Holmes J, Dai CY, Huang CF, Chung RT, et al. Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals. PLoS Genet. 2019;15(6):e1008181.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hamdane N, Juhling F, Crouchet E, El Saghire H, Thumann C, Oudot MA, Bandiera S, Saviano A, Ponsolles C, Roca Suarez AA, et al. HCV-induced epigenetic changes associated with liver cancer risk persist after sustained virologic response. Gastroenterology. 2019;156(8):2313–29.
Article
PubMed
Google Scholar
Carrero A, Berenguer J, Hontanon V, Navarro J, Hernandez-Quero J, Galindo MJ, Quereda C, Santos I, Tellez MJ, Ortega E, et al. Effects of Eradication of HCV on cardiovascular risk and preclinical atherosclerosis in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr. 2020;83(3):292–300.
Article
PubMed
Google Scholar
Wandrer F, Falk CS, John K, Skawran B, Manns MP, Schulze-Osthoff K, Bantel H. Interferon-mediated cytokine induction determines sustained virus control in chronic hepatitis C virus infection. J Infect Dis. 2016;213(5):746–54.
Article
CAS
PubMed
Google Scholar
Irshad M, Gupta P, Irshad K. Immunopathogenesis of liver injury during hepatitis C virus infection. Viral Immunol. 2019;32(3):112–20.
Article
CAS
PubMed
Google Scholar